Standard FDA-Approved Protocol (2.5 mL = 2.0 mg/mL)
| Week | Example amount (mg / mcg) | Units (per measurement) (mL) |
|---|---|---|
| Week 1 | 1 mg / 1000 mcg | 50 units (0.50 mL) |
| Weeks 2–12+ | 2 mg / 2000 mcg | 100 units (1.00 mL) |
Frequency: Measure once daily, preferably in the evening to coincide with nocturnal GH release[5][6]. The 2 mg example amount is the standard FDA-approved regimen for HIV lipodystrophy[7][8]. A one-week titration at 1 mg may improve tolerability before advancing to the full 2 mg dose.
Reconstitution Steps
- Draw 2.5 mL bacteriostatic water with a sterile syringe.
- Measure slowly down the vial wall; avoid foaming.
- Gently swirl until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
- Use within 7 days when reconstituted with bacteriostatic water[1].
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
How This Works
Tesamorelin mimics natural human GHRH by binding to pituitary GHRH receptors, triggering pulsatile growth hormone secretion and consequent IGF-1 elevation[2]. This cascade promotes lipolysis (fat breakdown), protein synthesis, and favorable metabolic shifts. In HIV-associated lipodystrophy, daily tesamorelin significantly reduces visceral adipose tissue and improves lipid profiles over 6–12 months[3][4]. Research also explores tesamorelin’s potential to reduce liver fat in NAFLD research samples and enhance cognitive function in older adults by restoring age-related GH/IGF-1 declines[4].